A sharp drop in Elan shares dragged the ISEQ sharply lower in Dublin on Friday after the pharmaceutical company announced that it had temporarily suspended trials of a new vaccine for Alzheimer's disease.
Elan, which accounts for over one fifth of the Dublin index, closed €5.27 lower - over 10% - at €45, helping to bring the ISEQ down by over 2%.
Elan said four patients in France were reported to be suffering from inflammation of the central nervous system, and it would suspend the trials until the cause could be found.
Elan is developing the vaccine, called AN-1792, with American Home Products.
